
Cancer Education · Research
Monitoring for Interstitial Lung Disease With Trastuzumab Deruxtecan: A Practice-Changing Case
Antibody-drug conjugates (ADCs) combine the precision of targeted therapy with the cell-killing power of chemotherapy, and few have been more transformative in breast cancer than fam-trastuzumab deruxtecan (T-DXd)
By Erica Doubleday, NP





























